阿替利珠单抗治疗晚期腺泡状软组织肉瘤的II期ALBERT试验
该II期试验纳入20例晚期腺泡状软组织肉瘤患者,阿替利珠单抗1200 mg每3周给药,主要终点客观缓解率(ORR)为10%(2/20),其中2例完全缓解持续超过1年,疾病控制率80%。应答者治疗前肿瘤组织CD8+PD-1+ T细胞浸润丰富且Tim-3和LAG-3低表达,提示CD8+PD1+ T细胞程度可能为预测应答的生物标志物。
要点
- 阿替利珠单抗在部分晚期ASPS患者中有效,ORR 10%,2例完全缓解持续超过1年。
- 疾病控制率达80%,70%患者达疾病稳定。
- 应答者基线CD8+PD-1+ T细胞浸润丰富,可能作为预测生物标志物。
核心结论
- 阿替利珠单抗在部分晚期ASPS患者中有效,无论既往是否接受帕唑帕尼治疗。
- 应答者治疗前存在显著的PD-1表达CD8+ T细胞浸润。
- CD8+PD1+ T细胞程度可能是预测阿替利珠单抗应答的潜在生物标志物。
研究设计与样本
- II期临床试验(ALBERT试验/NCCH1907),纳入20例年龄≥16岁的ASPS患者。
- 阿替利珠单抗剂量为1200 mg每3周一次,主要终点为客观缓解率(ORR)。
- 对肿瘤组织进行免疫组化、RNA测序和全外显子组测序以分析免疫和基因组特征。
主要发现
- 中位年龄32.5岁,12例(60%)既往接受过帕唑帕尼治疗。
- 总体ORR为10%(2/20),2例(10%)达完全缓解且持续超过1年。
- 应答者肿瘤组织显示CD8+PD-1+ T细胞丰富浸润,且Tim-3和LAG-3低表达。
关键数值与推荐
- 客观缓解率(ORR)为10%(2/20)。
- 完全缓解率为10%(2/20),持续超过1年。
临床怎么用
- 阿替利珠单抗可作为部分晚期ASPS患者的治疗选择,尤其既往接受过帕唑帕尼者仍可能获益。
- 治疗前肿瘤组织CD8+PD-1+ T细胞浸润程度可能有助于筛选潜在应答患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Alveolar soft part sarcoma (ASPS) is a rare subtype of soft tissue sarcoma with a high metastatic potential. We conducted a phase II clinical study of atezolizumab in ASPS patients to evaluate its efficacy, safety, and biomarkers associated with therapeutic response. PATIENTS AND METHODS: Eligible patients were aged ≥ 16 years and diagnosed with ASPS. Atezolizumab was administered at a dose of 1200 mg every 3 weeks. The primary endpoint was the objective response rate (ORR). Immune and genomic profiling of tissues was performed using immunohistochemistry, RNA sequencing, and whole-exome sequencing. RESULTS: Twenty patients were included in the study. The median age was 32.5 years, and 12 patients (60 %) received pazopanib. The overall ORR was 10 % (2 of 20). Two patients (10 %) achieved a complete response, which persisted for more than 1 year. Fourteen patients (70 %) had stable disease. The disease control rate was 80 %. Responders exhibited abundant infiltration of CD8+PD-1+ T cells, characterised by low expression of Tim-3 and LAG-3. CONCLUSION: Atezolizumab was effective in some patients, regardless of prior treatment with pazopanib. Responders had significant PD-1 expressing CD8+ T cell infiltration before immune checkpoint inhibitor therapy. The degree of CD8+PD1+ T cells may be a potential biomarker for predicting responses to atezolizumab.
引用
- Kojima Y, Watanabe K, Arakaki M, et al. Clinical, immunological, and genomic findings of atezolizumab in advanced alveolar soft part sarcoma: A phase II trial (ALBERT trial/NCCH1907). Eur J Cancer. 2025. PMID: 41242041. doi:10.1016/j.ejca.2025.116104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。